Biogen Idec Options Isis Pharmaceuticals’ Antisense Drug for Spinal Muscular Atrophy

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 20 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1672     ISSN: 1756-7874

Section: Licensing



Biogen Idec has agreed to pay Isis Pharmaceuticals up to US$299 M to gain rights over ISIS-SMNRx, an antisense drug in Phase I development for spinal muscular atrophy (SMA)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details